Modeling trajectories of regional volume loss in progressive supranuclear palsy

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1117-1124

  Josephs, Keith A ^a   Xia, Rong ^a   Mandrekar, Jay ^a   Gunter, Jeffrey L ^a   Senjem, Matthew L ^a   Jack, Clifford R ^a   Whitwell, Jennifer L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Longitudinal; Midbrain; Mixed effects models; PSP; Rates

Indexed keywords

AGED; ARTICLE; BRAIN ATROPHY; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; EXECUTIVE FUNCTION; EYE MOVEMENT DISORDER; FEMALE; FRONTAL LOBE; GAIT DISORDER; GLOBUS PALLIDUS; HEART VENTRICLE VOLUME; HUMAN; ILLNESS TRAJECTORY; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PARS OPERCULARIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; TEMPORAL LOBE; THALAMUS;

LONGITUDINAL; MIDBRAIN; MIXED-EFFECTS MODELS; PSP; RATES;

AGED; AGED, 80 AND OVER; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUPRANUCLEAR PALSY, PROGRESSIVE; TIME FACTORS;

EID: 84881542898     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25437     Document Type: Article

References (39)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
2. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
3. Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18:1018-1026.
4. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012;8:85-93.
5. Josephs KA, Whitwell JL, Dickson DW, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of aging 2008;29:280-289.
6. Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004;23:663-669.
7. Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2006;77:457-463.
8. Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 2011;17:599-605.
9. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006;129:1040-1049.
10. Whitwell JL, Jack CR Jr, Parisi JE, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007;130:1148-1158.
11. Josephs KA, Whitwell JL, Boeve BF, et al. Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Ann Neurol 2006;59:200-203.
12. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
13. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
15. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-1565.
16. Jack CR, Jr., Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685-691.
17. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999;9:179-194.
18. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000;97:11050-11055.
19. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9:195-207.
20. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11-22.
21. Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007;116:37-42.
22. Whitwell JL, Xu J, Mandrekar JN, Gunter JL, Jack CR Jr, Josephs KA. Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. Parkinsonism Relat Disord 2012;18:252-256.
23. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16:623-629.
24. Gunter JL, Shiung MM, Manduca A, Jack CR Jr. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging 2003;18:16-24.
25. Roy A. Estimating correlation coefficient between two variables with repeated observations using mixed effects model. Biom J 2006;48:286-301.
26. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 2-correlation between subjects. BMJ 1995;310:633.
27. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1-correlation within subjects. BMJ 1995;310:446.
28. Josephs KA, Whitwell JL, Eggers SD, Senjem ML, Jack CR Jr. Gray matter correlates of behavioral severity in progressive supranuclear palsy. Mov Disord 2011;26:493-498.
29. Looi JC, Macfarlane MD, Walterfang M, et al. Morphometric analysis of subcortical structures in progressive supranuclear palsy: In vivo evidence of neostriatal and mesencephalic atrophy. Psychiatry Res 2011;194:163-175.
30. Messina D, Cerasa A, Condino F, et al. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 2011;17:172-176.
31. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
32. Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008;131:2690-2700.
33. Agosta F, Kostic VS, Galantucci S, et al. The in vivo distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. Eur J Neurosci 2010;32:640-647.
34. Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63:81-86.
35. Lehericy S, Hartmann A, Lannuzel A, et al. Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy. Brain 2010;133:2410-2425.
36. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
37. Dickson DW. Neuropathology of progressive supranuclear palsy. Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Vol. 88. Amsterdam, The Netherlands: Elseveir; 2008;89:487-491.
38. Ahmed Z, Josephs KA, Gonzalez J, DelleDonne A, Dickson DW. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain 2008;131:460-472.
39. Whitwell JL, Master AV, Avula R, et al. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol 2011;68:753-760.